Medicare Covers GLP-1 Weight-Loss Drugs Starting July 1
For the first time, qualifying Medicare beneficiaries can access GLP-1 weight-loss drugs at $50 a month beginning July 1.
Medicare will begin covering GLP-1 weight-loss medications for qualifying beneficiaries on July 1, marking the first time older Americans on the federal health program can access these drugs for obesity treatment. The out-of-pocket cost for eligible enrollees is capped at $50 per month, a significant development for a class of drugs that can cost hundreds of dollars monthly without coverage.
The expansion represents a major policy shift for Medicare, which has historically covered GLP-1 drugs such as semaglutide only when prescribed for Type 2 diabetes, not for weight loss alone. Millions of older adults who have struggled with obesity but lacked a diabetes diagnosis were previously shut out of coverage, leaving many unable to afford the treatment on fixed incomes.
Read more SEED OK Program Gave Newborns $1,000 Before Trump Accounts →
However, healthcare experts are urging new users to weigh the risks alongside the benefits. GLP-1 medications are associated with notable side effects including nausea, vomiting, and gastrointestinal discomfort, particularly in the early weeks of use. Of particular concern for older adults is the potential for significant muscle loss alongside fat loss, which can exacerbate age-related muscle decline and raise the risk of falls and frailty.
Beneficiaries considering the drugs are advised to consult their doctors about whether they qualify under Medicare's criteria and to discuss strategies for preserving muscle mass, such as increased protein intake and resistance exercise, while on the medication. The $50 monthly cap makes these drugs newly accessible, but informed decision-making remains essential for this population.
Continue reading at MarketWatch.com
